glp 1 news GLP-1 receptor agonists show promise in treating substance use disorders FDA warns Novo Nordisk of

Its very common for pharmaceutical companies to collect genetic data on their participants, she said

The possibility that GLP-1 receptor agonists may be effective for some substance use disorders is promising, but we need large randomized controlled trials to confirm benefit and clarify for whom they work best, he says

Rocio Pereira, MD, chief of Endocrinology at the safety-net hospital system Denver Health and an associate professor of medicine at the University of Colorado, says that many of her patients report that semaglutide helps them eat less and that it has become easier for them to eat healthy foods and avoid junk food since starting on the medication

Dont you need to tell them to exercise or something? I said, Thats a very biased response, Stanford says

Furthermore, the paper indicated that standard MyPlate guidance, typically based on a 2,000-calorie diet, may not be tailored for the lower caloric needs or specific nutritional challenges of individuals on GLP-1RA therapy

Clinical research also shows that some neuroimaging features observed in people with obesity resemble those seen in people with addiction, says Lorenzo Leggio, MD, PhD, clinical director of the National Institute on Drug Abuse and corresponding author of the JES paper